Blood–brain barrier pathology is recognised as a central factor in the development of many
neurological disorders, but much less is known about the role of the blood–brain barrier in …

The availability of long-acting injectable (LAI) antipsychotics for the treatment of
schizophrenia provides clinicians with options that deliver continuous drug exposure and …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

There are significant differences between men and women in the efficacy and tolerability of
antipsychotic drugs. Here, we provide a comprehensive overview of what is currently known …

Introduction: The blood–brain barrier (BBB) possesses an outstanding ability to protect the
brain against xenobiotics and potentially poisonous metabolites. Owing to this, ATP binding …

ABSTRACT Introduction: Second-generation antipsychotics (SGAs) are frequently co-
prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug …

Antiepileptic drugs (AEDs) are frequently co-prescribed with new antidepressants (ADs) or
new antipsychotics (APs). A PubMed search with no time limit was used to update the review …

Introduction: Combinations of newer antidepressants and second-generation antipsychotics
(SGAs) are frequently used by clinicians. Pharmacokinetic drug interaction (PK DI) and …

Atypical antipsychotics [also known as second-generation antipsychotics (SGAs)] have
become a mainstay therapeutic treatment intervention for patients with schizophrenia …

After the identification of the influence of serotonergic receptors in ameliorating the negative
symptoms associated with schizophrenia, atypical antipsychotics were developed by …